Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349214 · ClinicalTrials.gov registry record · Phase 3
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
A Phase 3 study of Sjogren Syndrome, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 506
- Enrollment target
- 20
- Study locations
NCT05349214 is a Phase 3 study of Sjogren Syndrome that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 506 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05349214, a Phase 3 study of Sjogren Syndrome, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 506 participants
- Enrollment target
- 20
- Study locations
Study Summary
A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL VAY736
Study Locations (20)
Florida
- Bay Area Arthritis And Osteoporosis - Brandon
- GNP Research - Cooper City
- Sarasota Arthritis Res Ctr - Sarasota
Illinois
- Clin Invest Specialists Inc - Orland Park
- Clinic of Robert Hozman - Skokie
- Clinical Investigation Specialists, Inc. - Wauconda
California
- Providence Medical Foundation - Fullerton
- Advanced Medical Research - La Palma
Georgia
- Augusta University Georgia - Augusta
- North Georgia Rheumatology Group - Lawrenceville
North Carolina
- On Site Clinical Solutions Llc - Charlotte
- Arthritis and Osteoporosis - Charlotte
Tennessee
- West Tennessee Research Institute - Jackson
- Ramesh C Gupta MD Memphis TN - Memphis
Kansas
- University of Kansas Hospital - Kansas City
Massachusetts
- Tufts School of Dental Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 506 participants |
| Start Date | 2022-08-04 |
| Est. Completion | 2027-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05349214
The ClinicalTrials.gov registry entry for NCT05349214 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 506 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05349214 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Illinois, California.
Frequently Asked Questions
What is clinical trial NCT05349214 about?
NCT05349214 is a clinical study titled "Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome". A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)
What is the current status of trial NCT05349214?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 506 participants. The study started on 2022-08-04. Estimated completion is 2027-05-13.
What conditions does trial NCT05349214 study?
This clinical trial studies the following conditions: Sjogren Syndrome.
What interventions are being tested in trial NCT05349214?
The interventions under investigation include: Placebo (OTHER), VAY736 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05349214?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05349214 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sjogren Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.